Home Biosimilar Antibodies Protein Tyrosine Kinase c-Met Telisotuzumab (Anti-HGFR / c-Met)
For research use only. Not for use in humans.

Telisotuzumab (Anti-HGFR / c-Met)

Synonyms: MET， HGF R

Telisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD.

Telisotuzumab (Anti-HGFR / c-Met)

Click to purchase the isotype control of Telisotuzumab (Anti-HGFR / c-Met)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Name Citation c-Met Others
Foretinib (GSK1363089, XL880) 94 KDR,Tie-2,VEGFR3/FLT4
PHA-665752 96 RON,Flk1
SU11274 67
SGX-523 137
BMS-777607 63 Axl,RON,Tyro3
Tivantinib 49
JNJ-38877605 55
PF-04217903 22
MGCD-265 analog 14 RON,VEGFR1,VEGFR2
BMS-754807 54 Insulin Receptor,IGF-1R,TrkB
BMS-794833 4 VEGFR2
AMG-208 2
MK-2461 5 c-Met (Y1235D),c-Met (Y1230C),c-Met (N1100)
Golvatinib (E7050) 8 VEGFR2
AMG-458 0
Tepotinib (EMD-1214063) 23
NVP-BVU972 1
XL092 0 VEGFR2,AXL,MER
UNC2025 7 FLT3,Mer,Axl
Ningetinib 0 Axl,VEGFR2
Elzovantinib (TPX-0022) 0 SRC,CSF1R
AMG-1 0 RON
Pamufetinib (TAS-115) 0 recombinant VEGFR2
JNJ-38877618(OMO-1) 0 MET (M1268T)
Altiratinib 3 MET Y1230C,TrkA,TrkC
SAR125844 0 MET Y1235D,MET M1250T,TRKA/NTRK1
Glumetinib 2
Savolitinib (AZD6094) 20 p-Met
CEP-40783 (RXDX-106) 7 Axl,Tyro3,MER
S49076 1 Mer,Axl,FGFR3
Merestinib (LY2801653) 11 DDR1,AXL,FLT3
AMG 337 2
NPS-1034 6 Axl
Amuvatinib (MP-470) 22 c-RET,RAD51,c-Kit (D816H)
Glesatinib 2 SMO
Terevalefim 1
Licochalcone D 1 Caspase,EGFR,JAK2
BAY-474 0
Bozitinib 1
Pulsatilla saponin D 1
Sodium L-Ascorbyl-2-Phosphate (SAP) 3
Norcantharidin 5 EGFR
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Telisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD.

Product Details

Molecular Weight 145.64 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07005102 RECRUITING Drug: Standard of Care|Drug: Telisotuzumab Adizutecan|Drug: Non-Squamous Non-Small Cell Lung Cancer AbbVie 2025-08-03 PHASE2; PHASE3
NCT07490301 RECRUITING Drug: Telisotuzumab adizutecan|Drug: Fluorouracil|Drug: Foli Metastatic Pancreatic Ductal Adenocarcinoma; PDAC AbbVie 2026-04-30 PHASE2; PHASE3
NCT07196644 RECRUITING Drug: Telisotuzumab Adizutecan Solid Tumors Harboring MET Amplification AbbVie 2025-12-01 PHASE2
NCT06628310 ACTIVE_NOT_RECRUITING Drug: Telisotuzumab Adizutecan|Drug: Budigalimab|Drug: Fluor Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma AbbVie 2024-12-13 PHASE2
NCT07155187 RECRUITING Drug: Telisotuzumab Adizutecan|Drug: Standard of Care|Drug: Non-Small Cell Lung Cancer AbbVie 2025-12-10 PHASE2; PHASE3
NCT07439094 RECRUITING Drug: CKD-703 Advanced Solid Tumors; Non-Small Cell Lung Cancer Chong Kun Dang Pharmaceutical 2026-04-16 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-08)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.